These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24215352)

  • 1. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
    Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
    J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.
    Petros AM; Swann SL; Song D; Swinger K; Park C; Zhang H; Wendt MD; Kunzer AR; Souers AJ; Sun C
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1484-8. PubMed ID: 24582986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
    Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
    Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
    Gloaguen C; Voisin-Chiret AS; Sopkova-de Oliveira Santos J; Fogha J; Gautier F; De Giorgi M; Burzicki G; Perato S; Pétigny-Lechartier C; Simonin-Le Jeune K; Brotin E; Goux D; N'Diaye M; Lambert B; Louis MH; Ligat L; Lopez F; Juin P; Bureau R; Rault S; Poulain L
    J Med Chem; 2015 Feb; 58(4):1644-68. PubMed ID: 25585174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
    Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
    ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
    Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
    ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
    Jokinen E; Koivunen JP
    Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.
    Schroeder GM; Wei D; Banfi P; Cai ZW; Lippy J; Menichincheri M; Modugno M; Naglich J; Penhallow B; Perez HL; Sack J; Schmidt RJ; Tebben A; Yan C; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3951-6. PubMed ID: 22608393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
    Zhou H; Aguilar A; Chen J; Bai L; Liu L; Meagher JL; Yang CY; McEachern D; Cong X; Stuckey JA; Wang S
    J Med Chem; 2012 Jul; 55(13):6149-61. PubMed ID: 22747598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
    Sleebs BE; Kersten WJ; Kulasegaram S; Nikolakopoulos G; Hatzis E; Moss RM; Parisot JP; Yang H; Czabotar PE; Fairlie WD; Lee EF; Adams JM; Chen L; van Delft MF; Lowes KN; Wei A; Huang DC; Colman PM; Street IP; Baell JB; Watson K; Lessene G
    J Med Chem; 2013 Jul; 56(13):5514-40. PubMed ID: 23767404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
    Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
    Guo J; Roberts L; Chen Z; Merta PJ; Glaser KB; Shah OJ
    PLoS One; 2015; 10(3):e0114363. PubMed ID: 25781882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
    Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.